|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-7-4
|
|
pubmed:abstractText |
Glucagon-like peptide-1-based therapy is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis and pancreatic and thyroid cancers. There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, given their effects on immune function.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Dipeptidyl-Peptidase IV Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Glucagon,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Venoms,
http://linkedlifedata.com/resource/pubmed/chemical/exenatide,
http://linkedlifedata.com/resource/pubmed/chemical/glucagon-like peptide receptor,
http://linkedlifedata.com/resource/pubmed/chemical/sitagliptin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1528-0012
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
141
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
150-6
|
|
pubmed:meshHeading |
pubmed-meshheading:21334333-Adverse Drug Reaction Reporting Systems,
pubmed-meshheading:21334333-Diabetes Mellitus, Type 2,
pubmed-meshheading:21334333-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:21334333-Humans,
pubmed-meshheading:21334333-Hypoglycemic Agents,
pubmed-meshheading:21334333-Odds Ratio,
pubmed-meshheading:21334333-Pancreatic Neoplasms,
pubmed-meshheading:21334333-Pancreatitis,
pubmed-meshheading:21334333-Peptides,
pubmed-meshheading:21334333-Pyrazines,
pubmed-meshheading:21334333-Receptors, Glucagon,
pubmed-meshheading:21334333-Risk Assessment,
pubmed-meshheading:21334333-Risk Factors,
pubmed-meshheading:21334333-Thyroid Neoplasms,
pubmed-meshheading:21334333-Triazoles,
pubmed-meshheading:21334333-United States,
pubmed-meshheading:21334333-United States Food and Drug Administration,
pubmed-meshheading:21334333-Venoms
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
|
|
pubmed:affiliation |
Larry L. Hillblom Islet Research Center at David Geffen School of Medicine and Department of Biomathematics, University of California, Los Angeles, California 90095-7073, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Webcasts
|
